Migraine and menopause: why perimenopause is the hardest time

Many women with migraine hear the same promise: "it will sort itself out at menopause". Sometimes that is true. But in the meantime there is perimenopause, and that is precisely the period when attacks often become more frequent, more disabling and harder to relieve.

This article sorts out what is established, what is plausible and what is not demonstrated. Above all it stresses a distinction that many women do not know about, and that can change a medical decision: do you have migraines with or without aura?

What perimenopause changes

Migraine is three times more frequent in women than in men, with a peak between 15 and 49^[9]. A 2025 review devoted specifically to the migraine / menopause intersection identifies perimenopause as a particularly critical period: cycle-related attacks increase there, and they are described as "more disabling and less amenable to treatment" than non-menstrual attacks^[3]. The authors also point to unmet treatment needs at this time of life.

Why? The best-supported explanation is not the one people assume. It is not a low estrogen level that triggers the attack, but its fall, estrogen withdrawal^[8]. And perimenopause is precisely the period when levels do not fall gently but fluctuate, sometimes abruptly. It is not the shortage that causes the problem, it is the instability.

We must nonetheless stay honest about the level of evidence. A critical review published in 2023 re-examines this estrogen withdrawal hypothesis and concludes that the available work suffers from small numbers, variable case definitions and methodological inconsistencies^[2]. It is the dominant hypothesis; it is not a certainty.

Does migraine disappear after menopause?

This is the question every woman with migraine asks, and the honest answer is: it depends who you ask.

A systematic review compared the findings according to the source of recruitment^[4]. General population studies show an improvement in migraine after menopause, while perimenopause itself tends to come with a worsening. But patients recruited in headache centers (that is, the most severe migraines) show no improvement, and may even get worse.

Another useful nuance: menopause that occurs naturally is associated with better outcomes than a surgical menopause.

What to take away, then: improvement after menopause is a population trend, not an individual promise. If you are told "wait, it will pass", you are entitled not to settle for that.

Migraine and stroke risk: the figure to read correctly

Here, precision is a duty. You will often read that "migraine doubles the risk of stroke". That is true in relative risk, and very misleading if you stop there.

A large Danish population cohort, matched and followed for 19 years, gives the absolute risks^[5]: per 1,000 people with migraine, there were 45 ischemic strokes, against 25 per 1,000 in the general population. The adjusted hazard ratio is indeed 2.26, but in concrete terms this represents roughly two extra cases per 100 people over nearly twenty years. The risk is real, it is raised, and it stays low in absolute terms.

Three points matter. The associations were stronger in women and in people with aura. This is an observational study: migraine may be a risk marker rather than a cause. And finally, people identified through hospital registers have more severe migraines than average.

What this study does not say: that you should have an urgent cardiovascular work-up because you get migraines. It tests no screening strategy.

With or without aura: the distinction that changes a decision

An aura is a neurological symptom that comes before or with the attack: spots of light, jagged lines, a blind spot that spreads, sometimes tingling on one side or difficulty finding your words. It usually lasts from a few minutes to an hour. Many women have one without knowing it has a name, and therefore without reporting it.

Yet it is this distinction that guides the contraceptive decision. A systematic review covering four case-control studies and 12,256 women shows that the excess risk of ischemic stroke seen with low-dose combined pills (under 50 µg of ethinylestradiol) appears to be carried by migraine with aura^[7]. The authors specify that they could not pool the results into a single figure, so heterogeneous were the studies: there is therefore no "overall risk" to quote.

The European Headache Federation and the European Society of Contraception have published a joint consensus statement on this point^[6]. In women with migraine with aura, they recommend putting safety first and applying specific precautions regarding combined hormonal contraception. The authors are transparent: the level of evidence remains low, and the caution recommended follows from the potential seriousness of the feared event, not from scientific certainty.

In practice: if you have migraine with aura and you use a combined pill, a patch or a ring, this is not a trivial choice. Talk about it. The formal eligibility criteria come from WHO guidance and national authorities, and the decision is made with a doctor. Note too: contraception and menopause hormone therapy are two hormonally and clinically different situations; what applies to one does not transfer to the other.

Does menopause hormone therapy help?

The reasoning is appealing: if it is fluctuation that triggers the attacks, stabilizing levels should help. A landmark review by an international specialist on the subject puts it this way: keeping estrogen levels stable can benefit migraine, but clinical trial data are limited^[8].

And the counterpoint must be mentioned: the 2015 systematic review reports that postmenopausal hormone therapy was associated with a worsening of migraine in observational population studies^[4]. Association is not causation, and this does not make it a contraindication, but it does rule out presenting hormone therapy as a solution to migraine.

A word on the route of administration, because the question keeps coming up. The transdermal route (gel, patch) is often preferred in practice for the stability of levels it provides and its lesser first-pass liver effect. This rationale is plausible and commonly taught. But none of the sources checked for this article demonstrates a superiority of the transdermal route on the criterion of "migraine frequency": trials directly comparing the two routes are lacking. So we will not put a figure on this point.

Finally, the anti-CGRP treatments, which have transformed migraine prevention in recent years. A 2026 review is explicit: they do reduce the overall frequency of attacks, but hormonally triggered attacks are relatively resistant to them and, above all, "the absence of dedicated clinical trials is a major limitation"^[10]. So we cannot claim that they are effective on menstrual or perimenopausal migraine.

When to see a doctor

Not urgently, but without delay: if your migraines change in rhythm, duration or intensity as you approach your fifties. If you have visual disturbances before your attacks, tingling on one side or difficulty finding your words: those are auras, and your doctor needs to know, in particular before any prescription of hormonal contraception or hormone therapy. If you take combined estrogen-progestogen contraception and you have migraine with aura, a reassessment is warranted. And if you take painkillers more than ten to fifteen days a month, the risk of medication-overuse headache deserves to be assessed.

As an emergency, without delay: a sudden headache, maximal from the outset, unlike anything you have known. An aura that lasts abnormally long, or neurological symptoms that persist after the attack (weakness on one side, speech disturbance, a visual disturbance that does not return to normal). A first aura after 50. A headache with fever, a stiff neck, confusion, or occurring after a head injury.

Frequently asked questions

Will my migraines disappear at menopause?

Not necessarily. General population surveys show an improvement after menopause, but women followed in specialist centers (that is, those whose migraines are the most severe) do not improve and may even get worse. A menopause that occurs naturally also seems more favorable than a surgical menopause. Improvement is a population trend, not an individual promise.

Is it true that migraine doubles the risk of stroke?

In relative risk, yes: a large Danish cohort gives an adjusted hazard ratio of 2.26. But you have to read the absolute risk: over 19 years, there were 45 ischemic strokes per 1,000 people with migraine against 25 per 1,000 in the general population, that is roughly two extra cases per 100 people over nearly twenty years. The risk is real and raised, but it stays low in absolute terms. It is also an observational association, not a demonstrated cause-and-effect relationship.

Can I take the pill if I have migraines?

It is the with-or-without-aura distinction that counts. The excess risk of ischemic stroke seen with low-dose combined pills appears to be carried by migraine with aura. In this situation, the European professional societies recommend putting safety first and applying specific precautions. The formal eligibility criteria come from WHO guidance and national authorities, and the decision is made with a doctor. Report your auras of your own accord: many women do not mention them because they do not know that is what they are.

Does menopause hormone therapy treat migraine?

No, and that is not what it is for. Stabilizing estrogen levels can help some women, but clinical trial data on this point are limited, and observational studies have even linked postmenopausal hormone therapy to a worsening of migraine. The transdermal route is often preferred in practice for the stability of levels it provides, but trials directly comparing the two routes for migraine are lacking.

Do the new anti-CGRP treatments work on hormonal migraines?

We cannot say so. These treatments have transformed migraine prevention in general, but a 2026 review stresses that hormonally triggered attacks are relatively resistant to them and, above all, that there is as yet no clinical trial dedicated to this indication. It is a lead, not a result.

⚠️ This article is provided for informational and educational purposes only. It does not replace medical advice, diagnosis or treatment. Always consult your doctor or a qualified health professional with any questions about your health.

How we work: our editorial method · Written and verified by Bouchra, editorial lead.

How we work: our editorial method · Written and verified by Bouchra, editorial lead.